INTRODUCTION
The huge outcome heterogeneity among cancer patients, which hinders their clinical management, cannot be explained solely by the genetic background of the cancer cells. Some of this variation is due to intratumoral heterogeneity, whereby tumours contain multiple cell populations, each with distinct characteristics of karyotype, receptors, antigenicity, etc. The relative abundance of each cell type varies considerably between tumours and even between parts of the same tumour (1) . However, the predominant cell type in desmoplastic tumours is the carcinoma-associated fibroblast (CAF) (2) .
To date, several genetic classifiers of colorectal cancer (CRC) have been identified (3) (4) (5) (6) but none of these is of relevance in relation to the stroma. In this manuscript we provide information about the importance of the transcriptomic status of fibroblasts to CRC prognosis.
Fibroblasts are ubiquitous mesenchymal cells with different vital functions during development, wound healing and disease. Depending on their anatomic location fibroblasts should be considered as different cell types since they have particular gene expression programs and different features according to their tissue specialization (7) . However, a stereotyped gene expression program in response to serum was identified in fibroblasts from ten different anatomic sites, revealing that in response to a wound many of the normal differentiated particularities of the fibroblasts in the wounded tissue are temporarily set aside in favour of a common response (8) . In addition this common serum response gene expression program was identified in many human tumours and was a powerful predictor of metastasis in different carcinomas. The transcriptomic program of serum response genes was used as a prototype of the fibroblasts activation pattern and the correlation of this expression in fibroblasts with a centroid of the differential expression in tumour samples displayed a powerful prognostic information generating a continuous score that can be scaled (9) .
It is already known that as tumour evolves, malignant cells educate surrounding stroma to create an adequate microenvironment for their convenience (10) . This education can be understood through the degree of activation of fibroblasts as a surrogate marker. In other words, as the fibroblasts interact with other cells in the tumour, fibroblasts progressively evolve, and this evolution could provide new biomarkers and valuable information for patient's outcome. Thus, according to the concept that there is a common serum response program in different fibroblasts, despite being considered different cells, we hypothesize that since the earliest start of tumorigenic process, when an oncogenic stress transforms an epithelial cell until the cell metastasizes, there is a common and monotonic response of the surrounding fibroblasts that can be measured and associated to prognosis. We call this response as the Fibroblasts Progression Genes (FPG). We used this common response signature (277 genes) to develop a 25-gene classifier that characterized each fibroblast type with respect to location and that was of prognostic value for classifying patients with primary tumours. We also defined and validated a 19-gene classifier, being the best from the 277 genes predicting recurrence in CRC patients.
This simple signature score has remarkable predictive capabilities that confirm the biological relevance of CAFs and their gene programs to cancer progression.
MATERIALS AND METHODS

Fibroblast isolation
We obtained fibroblast cultures from fresh surgical specimens resected from patients with primary colorectal carcinoma: normal colonic fibroblasts (NCFs=9) from the normal colonic mucosa at least 5-10 cm from the surgical margin, carcinoma-associated fibroblasts from the primary tumour (CAF-PTs=14) and carcinoma-associated fibroblasts (CAF-LMs=11) from fresh surgical specimens of liver metastases. All samples were collected under the supervision of the Ethics Committee of the Hospital Universitari de Bellvitge. These 34 samples comprise the MB dataset. Clinical baseline data of patients whose fibroblasts were isolated are in supplementary table 1. To establish primary cultures, we homogenized surgical specimens with Collagenase IV and Dispase in a MACS separation unit (Miltenyi Biotech, Auburn, CA, USA), depleted homogenates from epithelial cells using anti-EPCAM Dynabeads (Invitrogen), and positively selected fibroblasts using anti-fibroblast microbeads (reference 130-050-601Miltenyi Biotech, Auburn, CA, USA). Cells were then cultured in DMEMF12+10%FBS (Gibco) with added penicillin/streptomycin.
To confirm that cultures derived from tumor specimens were pure fibroblast cultures we used a 
Microarray procedures and signature definition
RNA from fibroblasts cultures in passage #3 was used to hybridize with the Affymetrix GeneChip Human Gene 1.0 ST Array. The microarray data were read, normalized, and transformed to numerical expression values using the justRMA function in the simpleaffy package (11) . Differentially expressed genes were identified using the multi-class Significance Analysis of Microarrays (SAM) technique, available in the samr package (12) .
We selected those probes that simultaneously displayed a Robust Multi-array Average (RMA) normalized expression value of >4 in the three fibroblast populations (MB dataset). This yielded 10,779 probes common to NCF, CAF-PT and CAF-LM. This rule was intended to exclude genes that had not normalized expression in at least one category, as well as background noise (Supplementary Figure 2) . The signature was defined as follows: FPGs (Fibroblast Progression Genes) (NCF>CAF-PT>CAF-LM and NCF<CAF-PT<CAF-LM), contained genes with a log nfold change (logFC) NCF vs. CAF-PT >1.5 and CAF-PT vs. CAF-LM >1.5 (179 genes) and CAF-PT vs. NCF >1.5 and CAF-LM vs. CAF-PT >1.5 (98 genes); q<0.05. Therefore, the FPG signature comprises genes whose expression level increased or decreased during the normal colonic mucosa-primary tumour-liver metastasis sequence.
Definition of FPG class prediction
The Prediction Analysis of Microarrays (PAM) (13) nearest shrunken centroid classifier was applied to the MB dataset to refine the 277 differentially expressed genes (FPGs) to derive a classifier that better characterized each class (normal colonic fibroblasts, NCFs; CAFs from the primary tumour CAF-PTs; and CAFs from the liver metastasis, CAF-LMs). PAM estimates the predicted error rate based on misclassification error, which is calculated by averaging the errors from each of the ten-fold cross validations (CVs).
The classifier was then validated in external datasets. GSE31279 (14) Finally, we computed a signature score for the genes of the classifier to assess its power in predicting patient survival in two independent datasets, GSE14333 (6) (31 Stage I, 64 Stage II, and 71 Stage III patients) and GSE33133 (16) . The signature score was obtained by summarising centered gene expression means and computing a z-score for each patient. The expression score for each patient was classified as high or low according to the cuff off provided by Euclidian distance in the ROC curve analysis.
Recurrence-prediction classifier development
We developed a recurrence signature from the 277 genes comprising the FPG signature. PAM analysis identified relevant genes for the classifier from GSE14333 (RMA-normalised) defining the recurrent and non-recurrent classes. Internal validation was done by the leave-one-out CV method. Validation was carried out with GSE17538 (5) (RMA-normalised).
We also computed the z-score (signature score normalised by SD) and classified patients as We chose these datasets for training and validation because data came from whole-tumour samples without any enrichment in tumour cells, ensuring a minimum stromal percentage between 30-50%.
Wound-healing assay
Fibroblasts were grown on P60 dishes until confluence. We made a small scratch with a yellow pipette tip. After several PBS washes to remove floating cells, we began the assay by adding 
Ontology analysis
The Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 was used to determine likely biological processes in which differentially expressed genes (FPGs) were involved. GO attributes of biological processes were listed, ordered by their FDR-adjusted qvalue of <0.05.
Determination of the 19-gene signature cell-type specificity
We used data from GSE39396 (17) to check the stromal specificity of the genes in our CAF signature. GSE39396 consisted of four cell type populations isolated by FACS from six different colorectal tumours: EPCAM+ epithelial cells, CD45+ inflammatory cells, CD31+ endothelial cells and FAPα+ carcinoma-associated fibroblasts.
Internal microarray validation
We internally validated the genes comprising the 25-gene signature by means of RT-PCR, confirming the results by western blot. The antibodies used for this purpose were rabbit antihuman SLC7A2 (HPA009169, Sigma-Aldrich, Tres Cantos, Madrid, Spain), rabbit anti-human TGFB2 (V) (sc-90, Santa Cruz Biotechnology, Inc., CA, USA) and rabbit anti-human ARHGDIB (Ab15198, Abcam, Cambridge, UK).
Statistical analysis
Kaplan-Meier and Cox regression analysis estimates for DFS and DSS were calculated and compared by the likelihood ratio tests. Recurrence and death from disease were considered events. 
RESULTS
Differential gene expression of fibroblasts along cancer progression
According to the overall design (Supplementary Figure 2) , we isolated fibroblasts (n=34) from the three microenvironments in which colorectal epithelial cells reside (normal colonic mucosa
[NCM], primary tumour and liver metastasis). Since fibroblasts from different locations seem to have particular transcriptomic programs but share a stereotyped gene expression pattern in response to serum (8) and this response can be scaled to predict prognosis (9), we aimed to establish whether there is a set of fibroblastic genes whose expression arises gradually according to their anatomic demarcation involved in the steps of CRC progression (NCF, CAF-PT and CAF-LM). After filtering data, 10,779 probes met the characteristics imposed (cartoon, Supplementary Figure 3A) , most of which corresponded to development-related ontologies (Table 1) . Interestingly, overexpressed genes in the sequence NCF-to-CAF-LM (low in NCF and high in CAF-LM) were also associated with wound-healing response, while in the opposite direction the biological processes seem to be enriched in inflammatory response. From these probes, we selected those that fulfilled the criterion of a >1.5-fold change (normalized log 2 value) in expression at each step at the same time (as illustrated in the cartoon, Supplementary Figure 3B ). We refer to this as monotonic gene expression during cancer progression, meaning that gene expression follows a decreasing or increasing monotonic function. By this means we identified 98 and 179 genes that were upregulated and downregulated, respectively, from NCF to CAF-LM (Supplementary Table 3 ). Together, these 277 genes were designated as the FPG signature (fibroblastic genes relevant to cancer progression; Supplementary Figure 3C ).
Refining the FPG signature: developing a classifier
We aimed to refine the FPG signature to determine the minimum number of genes whose expression levels characterize each class of fibroblast involved in CRC progression. Our 34 samples of fibroblasts (MB Dataset) were subjected to Prediction Analysis for Microarrays (PAM) using the nearest shrunken centroid method to define the classifier. Ten-fold crossvalidation was used, randomly dividing the samples into ten approximately equally sized parts.
All parts were balanced to ensure that the three classes (NCF, CAF-PT and CAF-LM) were The overall error rate after ten-fold cross-validation was 0.174 in the training samples ( Table 2 ).
The CAF-PT class was the biggest contributor to the misclassification, some samples being mistaken for CAF-LM and for NCF ( Figure 1A) . We validated the 25-gene signature in three independent datasets, two whole-tumour samples (Dataset LP and GSE22598) and one microdissected samples (GSE31279). The probability of correctly classifying a sample was very high ( Figure 1B , Table 2 ), enabling us to conclude that these 25 genes were those whose expression levels best characterize each fibroblast class. Therefore, depending on the average gene expression value we could discriminate whether a given sample was an NCM, a primary tumour or a liver metastasis.
Gene expression associated with risk of progression
The CAF-PT class exhibited the greatest variation of those considered. We attempted to check that misclassified samples could be associated with prognosis, on the assumption that CAF-PTs with a higher signature score (reaching a value typical of CAF-LM) were at greater risk (i.e., had a poorer prognosis) than CAF-PTs with a lower signature score ( Figure 1C To analyze the cell-type-specific expression of the 19-gene signature further, we used data from GSE39396 (17), consisting of FACS-purified cell types from 6 colorectal cancer patients.
Relative levels of cell-type-specific marker genes confirmed that most of the 19 genes are representative of the microenvironment compartment, especially from FAPα + CAFs, with the exception of CFTR, which was expressed by EPCAM+ cells (Figure 2A) . Additionally, since recruitment of fibroblasts is one of the characteristics of desmoplastic tumours, we performed a wound-healing assay to compare the migration of fibroblasts with high and low 19-gene signature scores. Fibroblasts with high signature scores had better migratory abilities, as illustrated in Figure 2B . 
In order to rank patients by their level of expression of the 19 genes, and assuming equal biological relevance for each of the 19 genes of the signature, we derived a score by calculating the average of the z-scores, applying a weight of +1 to overexpressed genes and of -1 to underexpressed genes. For patient's categorisation we used the Euclidian distance between sensitivity and specificity (ROC curve analysis; AUC=0.79, cut off = 0.187; Figure 3A and B).
The recurrence classifier identified 97 low-expression (58.4%) and 69 high-expression patients (41.6%)(OR = 3.47; Figure3C). Low-risk and high-risk patients had significantly different survival outcomes, measured as DFS (HR=5.49; 95% CI=2.86-10.53; P<0.0001; Figure 3D ). An independent cohort of 141 patients (GSE17538) was used to evaluate the performance of the signature score of the 19-gene classifier. In the validation set, 55 patients were defined as high risk (39%) and 86 as low risk (61%, Figure 3E ; AUC=0.81). The prevalence of this validation dataset was 24.1% and the positive and negative posterior probabilities were 50% (95% CI=36-64%) and 8% (95% CI=3.5-16.4%), respectively. Stratifying patients by stage, the prevalence for Stage II patients was 18%, with positive and negative posterior probabilities of 37% (95% CI=17-61%) and 6% (95% CI=1-22%), respectively. Interestingly, the clinical decision margin was wider for Stage III, with a prevalence of 39% and positive and negative posterior probabilities of 61% (95% CI=42-77%) and 16% (95% CI=6-34%), respectively, thus with a difference of 45 points. Univariant Cox regression analysis revealed that high-risk patients had an HR of 7.43 (P<0.0001) for DFS ( Figure 3G ; statistically significant also stratifying by stages, Figure 3H and I) and of 7.44 (P<0.0001) for disease-specific survival (DSS) ( Figure 3J ). In multivariate analysis, after adjusting for significant variables in univariate analysis (stage and grade) the classifier score remained statistically significant for DFS (HR=5.52, 95% CI=2.23-13.65, P<0.0001; Table 3 ). The 19-gene signature was also independently associated with DSS (P=0.004; Table 3 ). Additionally, the signature score as a continuous variable was also significant, increasing the risk of relapse (HR) 1.93 times per unit increase of the score (P<0.0001, 95% CI=1.47-2.53).
To confirm the prognostic value in Stage II patients, we used a third independent cohort of 90 patients (GSE33113). Using the cut off obtained from the training dataset ( Figure 4A ), the classifier also performed well in this third validation cohort (AUC=0.71; Figure 4B Figure 4D ). Interestingly, the prevalence in this cohort was 21% and the positive and negative posterior probabilities were 37% (95% CI=22-55%) and 10% (95% CI=4-23%). Moreover, the signature score as a continuous variable was also significant, increasing the risk of relapse (HR) 2.06 times per unit increase of the score (P=0.003, 95% CI=1.29-3.29).
Thus, for both validation datasets, the classifier clearly identified low-risk patients, particularly in the case of Stage II patients, who would benefit from the omission of chemotherapy, especially those who are T4N0 and thus clinically classified as being at higher risk.
Unfortunately, we only know the age, gender, recurrence status, grade (only for GSE17538), stage and survival time of the patients in these cohorts, since the authors who uploaded the data to the GEO (Gene Expression Omnibus) did not provide information about other characteristics.
DISCUSSION
Molecular biomarkers for predicting relapse of CRC are needed to improve the selection of patients who would benefit from an adjuvant treatment. Recently, the great importance of the stroma to the prognosis of various types of cancer, especially those with a high degree of desmoplasia, has become recognized. Our hypothesis is that differential gene expression between NCF, CAF-PT and CAF-LM would be useful for predicting relapse in primary tumours.
We identified a short list of genes of stromal fibroblasts from anatomical sites involved in colorectal carcinogenesis, whose transcriptional level was correlated with cancer progression.
These genes display a gradual increase/decrease in expression during cancer progression, from NCM to liver metastasis. The scalability observed for this response may link the regenerative capacities of different organs after an injury (i.e., liver) and the greater ability of CAF-LM to induce EMT phenotypes in epithelial cells more efficiently than in other types of myofibroblasts (36) . Many of these genes are associated with wound-healing and correlate with the activation status of fibroblasts. As an example, SERPINE1, POSTN, HBEGF, PTX3 or TGFβ2, IL1β and TGFβ1 responsive genes, increase from NCF to CAF-LM, being IL1β and response seems to be more effective in the more aggressive liver and primary tumours, and could explain the greater degree of desmoplasia that is associated with poor outcome (37) .
Regarding downregulated genes, there is an enrichment of genes involved in inflammatory processes. This fact might explain the better outcome of patients with an intense inflammationrelated component infiltration. Probably the lack of such CAF-derived molecules in the more aggressive tumours would avoid the recruitment of inflammatory cells to the tumour. In summary, this result strongly suggests that changes in colorectal tumour stroma have a crucial role in disease progression and outcome. Obviously, other fibroblast-specific genes could have prognostic value, although their level of expression would not be associated with the transition from normal fibroblasts to highly activated fibroblasts, since those genes would be differentially expressed in a particular microenvironment (e.g., they could be expressed in hepatic metastases but be absent from primary tumours).
Although fibroblasts from different demarcations display particular transcriptomic programs (38) , even considering each fibroblast type as a different cell, it is interesting to observe that the transcriptome is dynamic and plastic when confronted with a malignant cell, probably as a result of the crosstalk between the two compartments. This is particularly relevant if we consider that CAFs from the primary tumour are derived from local NCF when oncogenically stimulated (same anatomical demarcation), but CAF-LM are cells with a different origin.
Previous studies have not focused on the role of the three microenvironments in which CRC cells interact during tumour progression. Additionally, different stromal classifiers exist for breast (39) , prostate (40) , lung (41) and hepatocellular carcinoma (42) , but this issue has not so far been addressed with respect to CRC; instead, the focus has been on CAFs, the principal component of the stroma. We also identified a 19-gene signature that predicts disease outcome with remarkable accuracy in whole-tumour samples. been involved in cell migration and angiogenesis promotion in different desmoplastic tumours (43, 44) . INHBA (a TGFB family member) has been recently observed to be expressed in the sequence from normal colonic mucosa-colonic adenoma-colorectal adenocarcinoma (45) and has been associated with prognosis (46) . Elevated expression of POSTN is reported to be associated with the invasion and anchorage-independent growth of the metastatic process of head and neck squamous cell carcinoma (47) and the invasive neoplasm of the pancreas (48).
Furthermore, secreted POSTN was reported to trigger an epithelial-mesenchymal transition (EMT) through co-activation of EGFR and alpha 5 integrin (49). Other genes like NTM (neurotrimin) and DENND2A have not been yet involved in cancer processes neither in the stroma nor epithelium.
According to a previously reported gene signatures in colorectal cancer, we only found overlap between two genes (PDLIM3 and ULBP2) of our classifier and a recent molecular classification (50) , contributing also these genes to characterise the group of worst outcome.
We present different, complementary ways of interpreting the results that could be of great relevance, depending on the clinical scenario. Firstly, PAM analysis identifies the genes of relevance in terms of binary events (recurrence/non-recurrence) that are highly specific after cross-validation. Secondly, the signature score (equal weight for all genes) reveals the biological relevance of the genes selected by PAM, clearly demonstrating that this signature is an independent predictor of outcome, even for Stage III patients. This step is crucial before trying to develop a model that is more mathematically accurate albeit without a biological rationale. This reinforces the role of the stroma, and particularly fibroblasts, as important components of cancer progression, rather than as mere companions of malignant cells. 
significant for those Stage II T4N0, perforated, obstructed, poorly differentiated or MSS patients, who would otherwise be offered toxic adjuvant chemotherapy. In Stage III patients our signature also differentiates low-risk patients, but these results need to be corroborated in a larger series and in trials to convince oncologists to withhold chemotherapy completely from these patients, even those of the T2N1 subgroup, whose members have a better clinical prognosis.
In conclusion, using the transcriptomic signature of fibroblasts that we defined and specifically the 19-gene classifier derived from it in a clinical setting, we can provide accurate information about the risk of recurrence, and may facilitate the selection of patients at risk of recurrence, especially for high-risk Stage II patients who would benefit from adjuvant therapy.
The findings from the stratification of patients based exclusively on the CAF transcriptomic program indicate the need to develop therapeutic strategies focused on these cells, since they are the main components of desmoplastic tumours. Prospective studies are needed to determine whether treatment decisions based on our stromal 19-gene classifier could benefit patients. 
